FDAnews
www.fdanews.com/articles/145662-vanda-pharmaceuticals-acquires-rights-to-nk-1-receptor-antagonist-from-eli-lilly

Vanda Pharmaceuticals Acquires Rights to NK-1 Receptor Antagonist From Eli Lilly

April 16, 2012
Vanda Pharmaceuticals announced that it has acquired an exclusive world-wide license from Eli Lilly to develop and commercialize a small molecule neurokinin 1 receptor (NK-1R) antagonist for all human indications.
Genetic Engineering & Biotechnology News